Boehringer Mannheim Gmbh

Roche Diagnostics Gmbh

Boehringer Mannhelm Gmbh

Fritz Demmer

Heinrich Woog

Werner Gruber

Berthold Stemmle

Gerhard Winter

Alexander Wirl

Rolf-Dieter Gabel

Walter Preis

Hans-Jorg Markl

Werner Heller

Klaus Budde

Hans-J&ouml;rg Markl

The present invention concerns a process for the production of well-tolerated, preserved injection or infusion solutions containing human protein.

Process for the production of pharmaceutical preparations containing human protein for infusion or injection purposes

Process for the preparation of shaped, compressed controlled-release unit-dosage forms from a therapeutic active substance exhibiting a self-retarding release that depends on the magnitude of the force used for the compression. The process gives unit-dosage forms for which the release of the active substance is highly uniform, reproducibly identical and largely linear. To achieve this, the active substance and an additive charge that inhibits or compensates for the self-retardation of its release are processed into particles in the first stage of production, so that the preliminary compressed objects made from these particles without any further additives exhibit a rapid release (in comparison with the required controlled release) over the range of the force of compression envisaged for the production of the unit-dosage form in question, after which the particles are compressed in the second stage of production with a release-retarding agent to obtain the unit-dosage forms. The invention also relates to the unit-dosage forms thus obtained.

Process for the preparation of shaped, compressed controlled-release

Elongated, divisible tablet

Process for the production of multi-dose pharmaceutical preparations

Pharmaceutical aqueous solution of

The present invention provides an aqueous, alkaline injection solution of torasemide ready for injection, which contains a physiologically compatible alkaline buffer with a pH value of from 9.3 to 9.9 and with a buffer capacity of up to 0.1 val/liter together with an organic solvent in an amount of from 5 to 20% by weight selected from the group of polyethylene glycols with a molecular weight of from 100 to 1500, polypropylene glycols with a molecular weight of from 50 to 1000, glycerol, propylene glycol, ethanol and propanol, the torasemide being present in a concentration of from 2 to 40 mg/ml. Torasemide solutions are useful to inhibit inflammation or promote diuresis. The present invention also provides a process for the preparation of this solution, wherein torasemide is suspended in the above organic solvent brought into solution by the addition of aqueous alkali, adding the buffer and other adjuvants and adjusting the pH value to 9.3 to 9.9.

Composition for a stable vein compatible injectable solution of

The present invention provides a medicament containing 80 to 95% clodronate, 2 to 10% filling material and 1 to 10% lubricant. The present invention also provides a process for the production of a clodronate-containing medicament containing 80 to 95% clodronate, 2 to 10% filling material and 1 to 10% lubricant, wherein the dry components are mixed, moist granulated with an aqueous binding agent and the granulate obtained subsequently dried, a lubricant being additionally admixed with the final granulate in an amount of from 1 to 5% and the mixture thus obtained pressed into tablets or filled into capsules which have a rate of dissolving of &gt;90% after 30 minutes.

Clodronate-containing medicaments and a process for the preparation

The present invention provides a composition containing guar flour in the form of tablets for oral administration, said tablets having been produced by dry pressing guar flour with a particle size of 60 to 500 .mu.m. in admixture with 5 to 30% of highly dispersed silica gel.

Method for making a guar flour chewable dosage unit

Growing community of inventors

Hirschberg, Germany

Fritz Demmer